Why the study?
Does adjuvant chemotherapy containing doxorubicin increase the risk of long-term cardiac sequelae compared to CMF alone in patients with early breast cancer?
Does adjuvant chemotherapy containing doxorubicin increase the risk of long-term cardiac sequelae compared to CMF alone in patients with early breast cancer?
Long-term follow-up shows that doxorubicin at standard adjuvant doses for early breast cancer causes a small increase in systolic dysfunction but does not lead to significant clinical cardiac sequelae that outweigh its oncologic benefits.
No takes yet. Share an insight, caveat, or question.
May warrant echocardiographic surveillance after doxorubicin; leaves open net benefit versus CMF in broader early breast cancer populations.
Zambetti et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: